We inferred that the possible pharmacologic mechanisms by which CHM treatment acts on CHB patients with LC includes antiviral effects [11], potent antioxidant activity, inhibition of free-radical–induced hepatic fibrosis by reducing cytochrome C [12], decreasing HBx-associated pathways [13], and modifying the microenvironment of HCC [14]. This evidence concerns the gene CYCS and choroideremia.